At Idorsia, we want to transform the horizon of therapeutic options for the patients who suffer from diseases that we target with our research and development. This puts innovation at the heart of what we do, and it is in this area that we can have our greatest positive impact on society. Our highly efficient innovation process spans all stages, from the discovery of a promising compound to the final commercialization of the drug. This cycle involves multiple teams across the company, generating the evidence to demonstrate the safety and efficacy of our treatments, as required by health authorities worldwide.

Idorsia contributes to multiple research areas relevant to our business goals and collaborates with a number of scientific organizations so as to learn from others and share our experience in the areas in which we operate. In addition to regularly publishing preclinical and clinical data on our drug discovery pipeline in peer-reviewed scientific journals, we convene and participate in not-for-profit groups dedicated to advancing scientific research.

Furthermore, we support the education and development of students and academics, with a focus on chemistry and biology in our region, which includes Switzerland, Germany, and France. We supervise postgraduate students, bachelor’s degree students and apprentices, many of whom conduct research for their studies in our laboratories. Our scientists also give lectures in their areas of expertise and submit articles and papers to publications to share their perspectives and experience with the scientific community.